Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SKLB1608
- Development stage
- Unknown
- Lead developer
- Sichuan University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SKLB1608 is a novel, orally bioavailable multi-target tyrosine kinase inhibitor (TKI) developed by the State Key Laboratory of Biotherapy at West China Hospital, Sichuan University. It primarily targets Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), Fibroblast Growth Factor Receptor 1 (FGFR1), and Platelet-Derived Growth Factor Receptor beta (PDGFRβ). By inhibiting these kinases, SKLB1608 exerts potent anti-angiogenic and anti-tumor effects, disrupting the signaling pathways essential for tumor vascularization and proliferation. It is currently being evaluated in clinical trials for the treatment of advanced solid tumors, including non-small cell lung cancer (NSCLC).
Beyond the preview
Go deeper on SKLB1608.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SKLB1608.